Clinical Trials · NCT06976372
A Study to Evaluate AMG 133 Administered Subcutaneously in Participants With Overweight or Obesity
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Amgen
- Enrollment
- 120
- Start date
- Aug 2024
- Locations
- 3 sites, United States
- Primary endpoint
- Maximum Concentration (Cmax) of AMG 133